Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Skuldtech Secures EUR 1 Million to Develop New Diagnostics for Alzheimer's Disease

Published: Wednesday, September 11, 2013
Last Updated: Wednesday, September 11, 2013
Bookmark and Share
Skuldtech and AB Science to renew their collaboration agreementto bring to market a new treatment for Alzheimer's disease.

Skuldtech announces that it has secured EUR 1 million in funding from Bpifrance (French public financing structure) as part of a project on Alzheimer's disease that has received funding of EUR 8.6 million in total. The program is planned to last for four years, with the first results expected in 2018.
 
Skuldtech has joined forces with AB Science for this program, with the aim of developing a new therapy for the treatment of Alzheimer's disease. As part of the program, Skuldtech will develop a companion diagnostic for AB Science's masitinib molecule and a diagnostic for the validity of cognitive tests and tests to predict the progression of Alzheimer's disease.

Using blood samples taken as part of the Phase III trial of masitinib in Alzheimer's disease, Skuldtech will identify the blood biomarkers that will help make simple, reliable diagnostic tests available as a matter of routine. This will result in treatments that can be tailored to the patient and the ability to monitor sufferers as their disease progresses. The clinical trial of masitinib was launched in Europe and other countries in May 2013. It expects to recruit a total of 400 patients. Blood samples from these patients will contribute to the development of a companion diagnostic by making it possible to identify those individuals most likely to benefit from the treatment.
 
This approach has already proven successful in the development of a new treatment for pancreatic cancer that combines gemcitabine and masitinib, where Skuldtech identified new biomarkers predicting a favorable response to treatment. The results of this clinical study led to an application to the European Medicines Agency for Marketing Authorization (MA) for masitinib in combination with companion biomarkers.
 
Using further blood samples, Skuldtech will also develop a diagnostic for the validity of cognitive tests and tests predicting the progression (slow or rapid) of Alzheimer's disease.
 
This project builds on Skuldtech's recent success in identifying blood biomarkers associated with a cognitive score. The company identified two sets of new blood markers, each associated with two trisomy 21 patient populations with low and high IQs respectively. The results of this study were published in the European Journal of Human Genetics in February 2013 (i). By describing the blood transcriptional profile of each group, Skuldtech identified specific biomarkers corresponding to a level of response in cognitive tests. The company hopes to emulate this result in the Alzheimer's disease program.
 
Skuldtech is keen to use the funding to capitalize on its broadband sequencing-based technological platform, pairing it with proprietary bioinformatics and biostatistics programs to measure and confirm the stage of progression of Alzheimer's disease.
 
“This new partnership to work on Alzheimer's disease will strengthen Skuldtech's position in the field of personalized medicine and in the development of companion diagnostics associated with new treatments in phases of clinical trials,” said Didier Ritter, CEO, Skuldtech. “As well as bringing new diagnostics to market, we are also open to similar partnerships with other biotech companies or with pharmaceutical laboratories.”
 
Alzheimer's is the most frequently occurring neurodegenerative disease in the world, affecting around 6 per cent of over-65s. In the US, it is the sixth most common cause of mortality in the population.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Skuldtech Identifies New Predictive Markers for Pancreatic Cancer Survival
The companion diagnostic developed by Skuldtech from these biomarkers will make it possible to identify patients most likely to benefit from this new treatment.
Thursday, January 31, 2013
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Vital Protein in Healthy Fertilization Process Identified
Researchers at the National Institutes of Health have discovered a protein that plays a vital role in healthy egg-sperm union in mice.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!